NL-OMON40236已完成不适用
A randomized, double-blind, placebo controlled, four-period, cross-over study to evaluate the cognitive effects of single oral administration of roflumilast in aging-related memory impairment - ROF-ALZ_103
Takeda0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Healthy subject, aged 60 to 80 years, inclusive, at the time of informed consent.
- •2. Memory performance between 1 to 2 SD below (for Impaired Elderly) and between 0.5 SD below and 0.5 SD above (for Healthy Elderly) aged, gender, and education level corrected normative values assessed using the VLT.;For a complete list of all inclusion criteria, please see protocol page 34.
排除标准
- •1. Subjects with previous or existing major psychiatric symptoms.
- •2. Subjects received any investigational compound within 30 days prior to the study.
- •3 Subjects received Roflumilast in a previous study or as therapeutic agent.
- •For a complete list of all exclusion criteria, please see protocol page 34/35.
研究者
相似试验
进行中（未招募）
不适用
A randomized, double-blind, placebo controlled, three-way crossover study exploring the efficacy of AZD3778 compared with placebo and an oral antihistamine (loratadine) in a model of seasonal allergic rhinitis - N/AEUCTR2005-002805-21-SEAstraZeneca AB
已完成
不适用
A randomized, double-blind, placebo controlled, first in human study to investigate the safety, tolerability, and pharmacokinetic and pharmacodynamic response of SLN360 in subjects with elevated lipoprotein (a)atherosclerosisNL-OMON55119Silence Therapeutics plc18
进行中（未招募）
1 期
Study of efficacy and safety of secukinumab in subjects with moderate tosevere chronic plaque-type psoriasisPlaque psoriasisEUCTR2016-000524-25-HUovartis Pharma Services AG536
已完成
不适用
A randomized, double-blind, placebo-controlled first time into human study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of intranasal dosing with GSK2245035, a TLR7 agonist, in healthy volunteers and allergic rhiniticsAllergic reaction10024970hay feverNL-OMON36044GlaxoSmithKline75
已完成
2 期
A phase 2a proof of concept study to evaluate efficacy and safety of SAR443122 in patients with moderate to severe subacute or discoid/chronic cutaneous lupus erythematosusCTRI/2021/08/035384Sanofi Healthcare India Private Limited5